双激素人工胰腺全闭环控制成人1型糖尿病:门诊随机交叉试验
这项门诊随机交叉试验在23例成人1型糖尿病患者中比较了2周双激素(胰岛素与胰高血糖素)人工胰腺全闭环控制与2周开环控制(患者常规胰岛素泵治疗)。结果显示闭环期间血糖达标时间(70-180 mg/dL)中位数86.6%,显著高于开环的53.9%(P<0.0001),且无需餐食或运动告知,安全性良好。
要点
- 双激素全闭环人工胰腺显著提高成人1型糖尿病血糖达标时间。
- 闭环控制无需餐食或运动告知即可安全运行。
- 该门诊随机交叉试验支持双激素人工胰腺的临床应用潜力。
核心结论
- 在成人1型糖尿病患者中,与胰岛素泵治疗相比,双激素人工胰腺全闭环控制提供了更优的血糖控制,且无需餐食或运动告知,安全性良好。
研究设计与样本
- 门诊、随机、交叉试验,比较2周全闭环双激素人工胰腺治疗与2周开环控制(患者常规胰岛素泵治疗,如有血糖传感器则一并使用)。
- 共23例患者纳入分析。
主要发现
- 闭环期间血糖达标时间(70-180 mg/dL [3.9-10 mmol/L])中位数为86.6%(四分位距84.9-88.5),显著高于开环的53.9%(49.7-67.2),P<0.0001。
临床怎么用
- 双激素全闭环人工胰腺可在无需餐食或运动告知的情况下为成人1型糖尿病提供更优血糖控制,且安全性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To demonstrate the performance and safety of a bihormonal (insulin and glucagon) artificial pancreas (AP) in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this outpatient, randomized, crossover trial, 2-week fully closed loop glucose control (AP therapy) was compared with 2-week open loop control (patient's normal insulin pump therapy with a glucose sensor if they had one). RESULTS: A total of 23 patients were included in the analysis. Time in range (70-180 mg/dL [3.9-10 mmol/L]) was significantly higher during closed loop (median 86.6% of time [interquartile range 84.9-88.5]) compared with open loop (53.9% [49.7-67.2]; P < 0.0001). CONCLUSIONS: Compared with insulin pump therapy, the bihormonal AP provided superior glucose control, without meal or exercise announcements, and was safe in adults with type 1 diabetes.
引用
- Blauw H, Onvlee AJ, Klaassen M, et al. Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial. Diabetes Care. 2021. PMID: 33397767. doi:10.2337/dc20-2106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。